Evidence map›Paper›PMID 37593151›Full record

ArticleFrontiers in cardiovascular medicine2023

Heart rate reduction after genetic ablation of L-type Ca

Viviana Delgado-Betancourt, Kroekkiat Chinda, Pietro Mesirca, Christian Barrère, Aurélie Covinhes, Laura Gallot, Anne Vincent, Isabelle Bidaud, Sarawut Kumphune, Joël Nargeot and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 3 countries.

Viviana Delgado-BetancourtInstitut de Génomique Fonctionnelle, Université Montpellier, CNRS, INSERM, Montpellier, France.
Kroekkiat ChindaInstitut de Génomique Fonctionnelle, Université Montpellier, CNRS, INSERM, Montpellier, France.
Pietro MesircaInstitut de Génomique Fonctionnelle, Université Montpellier, CNRS, INSERM, Montpellier, France.
Christian BarrèreInstitut de Génomique Fonctionnelle, Université Montpellier, CNRS, INSERM, Montpellier, France.
Aurélie CovinhesInstitut de Génomique Fonctionnelle, Université Montpellier, CNRS, INSERM, Montpellier, France.
Laura GallotInstitut de Génomique Fonctionnelle, Université Montpellier, CNRS, INSERM, Montpellier, France.
Anne VincentInstitut de Génomique Fonctionnelle, Université Montpellier, CNRS, INSERM, Montpellier, France.
Isabelle BidaudInstitut de Génomique Fonctionnelle, Université Montpellier, CNRS, INSERM, Montpellier, France.
Sarawut KumphuneBiomedical Engineering Institute (BMEi), Chiang Mai University, Chiang Mai, Thailand.
Joël NargeotInstitut de Génomique Fonctionnelle, Université Montpellier, CNRS, INSERM, Montpellier, France.
Christophe PiotInstitut de Génomique Fonctionnelle, Université Montpellier, CNRS, INSERM, Montpellier, France.
Kevin WickmanDepartment of Pharmacology, University of Minnesota, Minneapolis, MN, United States.
Matteo Elia Mangoni *Institut de Génomique Fonctionnelle, Université Montpellier, CNRS, INSERM, Montpellier, France.
Stéphanie Barrère-Lemaire *Institut de Génomique Fonctionnelle, Université Montpellier, CNRS, INSERM, Montpellier, France.
Institut de Génomique Fonctionnelle · FRCentre National de la Recherche Scientifique · FRUniversité de Montpellier · FRChiang Mai University · THClinique du Millénaire · FRInserm · FRLaboratoire d'Excellence Canaux Ioniques d'Intérêt Thérapeutique · FRNaresuan University · THUniversity of Minnesota · US

Funding

The role of RGS proteins in the parasympathetic control of heart rateR01HL105550 · NHLBI · UNIVERSITY OF MINNESOTA · PI MARTEMYANOV, KIRILL A., WICKMAN, KEVIN D · 2011 to 2018
$3.2M
NHLBI NIH HHS R01 HL105550
6 · The paper itself

Abstract

Background: Acute myocardial infarction (AMI) is the major cause of cardiovascular mortality worldwide. Most ischemic episodes are triggered by an increase in heart rate, which induces an imbalance between myocardial oxygen delivery and consumption. Developing drugs that selectively reduce heart rate by inhibiting ion channels involved in heart rate control could provide more clinical benefits. The Ca Objective: We aimed to investigate the relationship between heart rate and infarct size using mouse strains knockout for Ca Methods: Wild-type (WT), Results: Conclusion: Our results show that decreasing heart rate allows to protect the myocardium against IR injury

Indexed as

cardioprotectioncav1.3 calcium channelgenetic modelheart rateheart rate reductionischemia-reperfusion injurymyocardial infarction

Identifiers

PMID37593151
PMCPMC10429177
OpenAlexW4385445191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.